Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
PETROCHINA
00857
HK Stock MarketDetailed Quotes
VISEN PHARMA-B (02561)
- 25.060
- -0.780-3.02%
Market Closed May 8 16:00 CST
2.86BMarket Cap-10.17P/E (TTM)
25.840High24.100Low17.50KVolume25.840Open25.840Prev Close429.67KTurnover0.02%Turnover RatioLossP/E (Static)113.93MShares54.00052wk High3.38P/B2.86BFloat Cap24.00052wk Low--Dividend TTM113.93MShs Float69.150Historical High--Dividend LFY6.73%Range %24.000Historical Low24.552Avg Price100Lot Size--Div Yield TTM--Div Yield LFY
02561 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
02561 Orderflow
Unit: --
02561 Orderflow Trend
IntradayDayWeekMonth
No Data
VISEN PHARMA-B (02561) News
Visen Pharmaceuticals Sets 2026 AGM to Approve Directors, Auditor and Share Mandates
VISEN PHARMA-B: 2025 Annual Report
VISEN Shareholders Clear Key Ascendis Licensing and Supply Deals
VitalSpring Pharmaceuticals rose as the first domestic prescription for Vizart is expected to be issued in June or July.
ViSheng Pharmaceutical-B (02561) surged over 9% in the afternoon trading session. As of the time of writing, it was up 8.77%, trading at HKD 28.28 with a turnover of HKD 1.4299 million.
VISEN Pharmaceuticals Raises Caps on Connected Licensing and Supply Deals With Ascendis
VISEN Pharmaceuticals Calls EGM to Approve Expanded Ascendis Licensing and Supply Deals
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"